Literature DB >> 33031815

Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review.

Genís Ona1, José Carlos Bouso2.   

Abstract

Microdosing psychedelic drugs-that is, taking sub-behavioral doses of lysergic acid diethylamide (LSD) or psilocybin-is a growing practice in Western societies. Taken mainly for creative or mood-enhancing purposes, thousands of users are increasingly being exposed to (micro)doses of psychedelic drugs. In this systematic review, we searched the available evidence from human studies, focusing our results in terms of three main axes: efficacy, safety, and the influence of the placebo effect in microdosing practices. While the available evidence has some strengths (e.g. large sample sizes, robust methodologies) there are also remarkable limitations (e.g. gender bias, heterogeneity of dosing schedules and drugs used). Highly contradictory results have been found, showing both the benefits and detriments of microdosing in terms of mood, creative processes, and energy, among other regards. This review provides a general overview of the methods and approaches used, which could be useful for improving future studies.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hallucinogens; LSD; Microdosing; Psilocybin; Psychedelic drugs

Mesh:

Substances:

Year:  2020        PMID: 33031815     DOI: 10.1016/j.neubiorev.2020.09.035

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  8 in total

Review 1.  Experimental Models to Study Skin Wound Healing with a Focus on Angiogenesis.

Authors:  Eberhard Grambow; Heiko Sorg; Christian G G Sorg; Daniel Strüder
Journal:  Med Sci (Basel)       Date:  2021-08-25

2.  Natural language signatures of psilocybin microdosing.

Authors:  Camila Sanz; Federico Cavanna; Stephanie Muller; Laura de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar; Facundo Carrillo; Adolfo M García; Carla Pallavicini; Enzo Tagliazucchi
Journal:  Psychopharmacology (Berl)       Date:  2022-06-09       Impact factor: 4.415

3.  Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Authors:  Joseph M Rootman; Maggie Kiraga; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P C Kuypers; Zach Walsh
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

4.  Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.

Authors:  Joyce Huang; Michelle Pham; William J Panenka; William G Honer; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2022-05-18       Impact factor: 5.435

5.  Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.

Authors:  Joseph M Rootman; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P C Kuypers; Vince Polito; Francoise Bourzat; Zach Walsh
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

6.  How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Authors:  Manon van den Berg; Igor Magaraggia; Rudy Schreiber; Todd M Hillhouse; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2022-03-29       Impact factor: 4.415

7.  Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.

Authors:  Carla Pallavicini; Enzo Tagliazucchi; Federico Cavanna; Stephanie Muller; Laura Alethia de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar
Journal:  Transl Psychiatry       Date:  2022-08-02       Impact factor: 7.989

8.  Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.

Authors:  Dóra Révész; Genís Ona; Giordano N Rossi; Juliana M Rocha; Rafael G Dos Santos; Jaime E C Hallak; Miguel Á Alcázar-Córcoles; José C Bouso
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 5.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.